The study, led by Laurine Noblecourt, Amanda Wicki and Benoit Van den Eynde of the Van den Eynde laboratory, together with former senior immunologist Carol Leung, who is now Group Leader at the NDM Centre for Immuno-Oncology, is published in the current issue of Cancer Cell. The researchers describe how the combination of carboplatin and paclitaxel, a regimen widely known as CarboTaxol, as well as the drug cyclophosphamide, can function as adjuvants, meaning substances that boost the effectiveness of vaccines, in preclinical models of cancer. Critically, the team found that this therapeutic effect is further enhanced when the combined regimen is supplemented with anti-PD-1 immune checkpoint blockade, an immunotherapy that prevents T cell exhaustion and thereby intensifies the T cell assault on tumors. The finding suggests that a carefully orchestrated triple combination of chemotherapy, vaccine and checkpoint inhibitor could deliver far greater tumor control than any of the components alone.

Our studies demonstrate in preclinical models of cancer that, if correctly timed, the combination of these chemotherapies with a cancer vaccine can synergize with ICB to enhance tumor control and significantly extend survival, said Leung. This therapeutic effect stems from the direct modulation of key functional traits of CD8+ T cells by the chemotherapies, which enables a better response to subsequent vaccination and, possibly, to anti-PD-1 ICB as well. The statement captures the central surprise of the work: rather than merely avoiding damage to the immune system, the chemotherapies appear to actively reprogram T cells into a state that primes them for stronger responses down the line. This is a direct, cell-intrinsic effect, not simply an indirect consequence of killing tumor cells or depleting suppressive immune populations.

That is not to say the indirect mechanisms were unknown. Previous studies have shown that in some cancers, chemotherapies can support immune checkpoint blockade by depleting immune cells within tumors that suppress anti-cancer immune responses. Chemotherapies can also stimulate anti-tumor immunity in another way: when they kill cancer cells, they release a variety of cancer antigens into the open, exposing them to the immune system and potentially broadening the immune response. But how chemotherapies might affect vaccine-induced immune responses to tumors specifically had never been methodically examined until now. Most clinical trials evaluating cancer vaccines administer the experimental therapy alongside chemotherapy simply because chemo is the standard of care, Noblecourt explained. But they do so without reference to established evidence on how chemotherapies affect vaccine responses. In other words, the field has been combining two powerful tools in the dark, with no systematic understanding of whether the pairing helps, hurts, or does nothing at all.

To fill that gap, the Ludwig Oxford team tested the effects of a panel of chemotherapies on the efficacy of a cancer vaccine developed in the Van den Eynde laboratory. The vaccine targets the non-human analogue of a common cancer antigen identified and characterized by Ludwig researchers, and it is delivered in two shots given days apart, a schedule immunologists call the prime and boost doses. The prime dose initiates the immune response, coaxing naive T cells into an activated state, while the boost dose expands and refines that response, driving the production of a larger and more potent army of antigen-specific T cells. Against this backdrop, the researchers administered various chemotherapy agents and measured how the resulting T cell populations and tumor outcomes changed across several preclinical cancer models.

The results were striking. CarboTaxol improved the efficacy of the vaccine when it was given with either the prime or the boost dose. Chemotherapies enhanced vaccine-induced CD8+ T cell responses against the targeted cancer antigen, expanded the pool of tumor-targeting CD8+ T cells and extended survival in preclinical models, said Noblecourt. This effect was further enhanced by ICB. Yet the experiments also revealed that timing was everything. The adjuvant effect of CarboTaxol was only seen when it was administered on the same day as the vaccine, and it was lost entirely if the chemotherapy and the vaccine were administered days apart. This temporal sensitivity is a detail with enormous clinical consequences, because it implies that trials which casually pair vaccines with standard chemotherapy schedules may be squandering a substantial therapeutic opportunity, or even undermining their own results, without ever knowing it.

Mechanistically, the researchers traced the effect to a specific population of CD8+ T cells that express a transcription factor known as TCF1. A master regulator of gene expression, TCF1 switches on genes that rejuvenate CD8+ T cells, extending their lifespan, their functionality and their ability to establish an immunological memory of an encountered antigen. In the hierarchy of anti-tumor immunity, TCF1-positive T cells occupy a privileged position. They behave somewhat like stem cells of the immune response, self-renewing and continuously feeding the front line with fresh effector cells that do the actual work of killing tumor cells. CD8+ T cells that express TCF1 are of critical importance to initiating and sustaining anti-cancer immune responses, said Wicki. The expansion of these cells by chemotherapy occurred independently of vaccination and established a deep pool of T cells for mobilization upon subsequent exposure to the vaccine antigen. The chemotherapy, in effect, digs a reservoir that the vaccine later draws upon.

Importantly, the team did not leave the finding confined to the laboratory. In support of the clinical relevance of their results, the researchers showed that the expansion of TCF1-positive CD8+ T cells could also be observed in samples taken from two independent cohorts of patients with different types of cancer who had been treated with CarboTaxol. This translational evidence matters because preclinical immunology has a long history of effects that fail to survive contact with human biology. Seeing the same cellular signature in patient samples treated with a standard-of-care regimen suggests that the mechanism operates in real clinical settings, and that the timing strategy validated in mice could plausibly be translated into trial design for human patients without requiring entirely new drugs.

Our findings have significant implications for clinical trials of cancer vaccines, said Van den Eynde. Current studies may not be taking advantage of a potential adjuvant effect that might be obtained by simply altering the timing of vaccination relative to chemotherapy. Our study paves the way to defining the optimal interval to induce such synergies. Further, because TCF1-positive CD8+ T cells are important for optimal responses to ICB as well, the mechanism we have identified here may extend beyond vaccines to other immunotherapy combinations. At the very least, our findings support the clinical evaluation of the combination of cancer vaccine, chemotherapy and anti-PD-1 checkpoint blockade examined in this study. The implication is remarkable in its economy: no new drug, no new target and no new manufacturing pipeline would be required, only a rational rescheduling of therapies that already exist and are already approved.

The study was supported by the Ludwig Institute for Cancer Research, the Berrow Foundation, the Swiss National Science Foundation and the Academy of Medical Sciences in the U.K. Beyond its immediate findings, the work reframes how the field should think about the interaction between cytotoxic therapy and immunotherapy. Rather than viewing chemotherapy as a necessary evil to be tolerated while the immune system is engaged, oncologists may come to see it as an active partner whose schedule, dose and pairing can be engineered to build, rather than burn, the anti-tumor immune response. If the same-day synergy and the TCF1-driven expansion hold up in clinical evaluation, the humble chemotherapy infusion could find an unexpected second career as one of the most powerful vaccine boosters in the oncology arsenal.

Subject of Research: How chemotherapy timing enhances CD8+ T cell responses and boosts cancer vaccine efficacy

Article Title: Chemo as a booster of cancer vaccines

Article References: Chemo as a booster of cancer vaccines. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cancer vaccines, chemotherapy, CarboTaxol, CD8+ T cells, TCF1, immune checkpoint blockade, anti-PD-1, adjuvants, immunotherapy, Ludwig Institute for Cancer Research, Cancer Cell, tumor immunology